Head-to-head evidence
tralokinumab vs Zumilokibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: IL-13 · full Atopic Dermatitis pipeline
tralokinumab · Adbry
Marketed by AstraZeneca and partners
NCT05958407 · Phase 3 · completed
The 235 participants were randomized 2:1 to tralokinumab or placebo and the initial 16-week comparison was double-blinded. The primary clinical endpoint—an Investigator’s Global Assessment score of 0 or 1 at Week 16—was met, occurring in 40.0% of the tralokinumab group versus 10.6% of the placebo group (p<.001).
Next expected readout: October 2026 · NCT06311682 (registry estimate)
Zumilokibart
Developed by Apogee Therapeutics and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: November 2026 · NCT06395948 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: tralokinumab's landscape · Zumilokibart's landscape